Journal of Ophthalmic & Vision Research最新文献

{"title":"Optical Coherence Tomography Angiography Changes in Diabetic Macular Ischemia after Systemic Normobaric Oxygen Therapy.","authors":"Diba Idani, Seyed Mohammadjavad Mashhadi, Hamze Babaei, Farideh Sharifipour, Ramin Nourinia, Bahareh Kheiri, Arezoo Miraftabi","doi":"10.18502/jovr.v20.15354","DOIUrl":"10.18502/jovr.v20.15354","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate vascular changes on optical coherence tomography angiography (OCTA) in patients with diabetic macular ischemia (DMI) after systemic normobaric oxygen (NBO) therapy.</p><p><strong>Methods: </strong>This before-after interventional studyincluded 26 eyes of 26 patients with DMI.Macular OCTA was performed before and after 1 hour of 100% NBO therapy at a flow of 10 L/min delivered by face mask. As primary outcomes, changes in OCTA metrics were evaluated using the paired <i>t</i>-test. Subgroup analyses were performed based on gender. The secondary outcomes included identifying parameters correlated with best-corrected visual acuity (BCVA) and factors associated with improvement in OCTA parameters.</p><p><strong>Results: </strong>The patients included 15 males and 11 females aged 59.48 <math><mo>±</mo></math> 9.67 years. Overall, no significant change was observed in retinal thickness; however, there was a significant decrease in retinal thickness among females and a significant increase among males (<i>P</i> <math><mo><</mo></math> 0.001). The foveal avascular zone (FAZ) decreased significantly from 0.38 <math><mo>±</mo></math> 0.14 to 0.34 <math><mo>±</mo></math> 0.12 mm² (<i>P =</i> 0.035). Superficial capillary plexus vessel density (SCP-VD) and deep capillary plexus vessel density (DCP-VD) at fovea increased from 13.5 <math><mo>±</mo></math> 6.37 to 14.98 <math><mo>±</mo></math> 6.33% (<i>P =</i> 0.059) and from 24.61 <math><mo>±</mo></math> 6.75 to 26.59 <math><mo>±</mo></math> 6.16% (<i>P =</i> 0.022), respectively. In males, BCVA correlated significantly with baseline DCP parameters but corresponded with none of the SCP parameters. In females, BCVA significantly correlated with pre-O2 DCP-VD of the perifoveal inferior quadrant. Finally, regression analysis did not show any parameter that could predict a favorable response.</p><p><strong>Conclusion: </strong>Using OCTA, we observed a decrease in FAZ and an increase in DCP-VD at fovea after short-term NBO therapy for patients with DMI.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phacoemulsification and Visco-synechiolysis With or Without Trabeculectomy Following Initial Management of Acute Primary Angle Closure: A Comparative Study.","authors":"Mahdi Sharifzadeh Kermani, Mina Haj-Mohammad Karimi, Ali Sharifi, Mahla Shadravan, Arash Daneshtalab, Amin Zand","doi":"10.18502/jovr.v20.15048","DOIUrl":"10.18502/jovr.v20.15048","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the effects of phacoemulsification, visco-synechiolysis, and trabeculectomy on eyes with a recent history of acute primary angle closure (APAC).</p><p><strong>Methods: </strong>In this prospective nonrandomized study, we enrolled patients with cataracts, peripheral anterior synechiae (PAS), and a history of APAC attack managed with medications and laser peripheral iridotomy (LPI) within the past six weeks. Patients without signs of glaucomatous optic neuropathy (GON) underwent phacoemulsification and visco-synechiolysis (PV group). Trabeculectomy was added to this procedure for cases with signs of underlying chronic GON (PVT group). We evaluated best-corrected visual acuity (BCVA), intraocular pressure (IOP), angle opening, PAS extension, and adverse events at baseline and six months postoperatively.</p><p><strong>Results: </strong>The PV and PVT groups comprised 8 and 12 eyes, respectively. At month six, both groups showed significant improvement in BCVA, reduced IOP, and increased Shaffer grading scores compared to baseline (all <i>P</i>s <math><mo><</mo></math> 0.05). Extensive PAS ( <math><mo>≥</mo></math> 180º) significantly decreased at month six in both the PV (<i>P</i> = 0.008) and PVT (<i>P</i> = 0.002) groups compared to baseline. However, its prevalence did not significantly differ between the two groups at baseline (<i>P</i> = 0.288) or six months after surgery (<i>P</i> = 0.881). At month six, IOP was significantly lower in the PVT group than the PV group (10.83 <math><mo>±</mo></math> 1.40 vs 13.63 <math><mo>±</mo></math> 2.07 mmHg, <i>P</i> = 0.002). Nevertheless, BCVA and Shaffer grading scores were not different between the two groups at this time point (<i>P</i> = 0.120, and <i>P</i> = 0.891, respectively). No serious complications were observed in any groups during the follow-ups.</p><p><strong>Conclusion: </strong>Patients with cataracts and a recent history of APAC without underlying chronic glaucoma may not receive additional trabeculectomy alongside lens extraction and synechiolysis.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilocarpine 1% for Improved Near Vision in Pseudophakic Patients.","authors":"Alireza Peyman, Maryam Naderi-Lordejani, Matin Irajpour, Mohammad Javad Ghanbarnia, Nima Koosha, Mohsen Pourazizi","doi":"10.18502/jovr.v20.15331","DOIUrl":"10.18502/jovr.v20.15331","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of 1% pilocarpine to enhance near vision in pseudophakic patients with monofocal intraocular lens (IOL).</p><p><strong>Methods: </strong>This prospective, nonrandomized, open-label, pre-post interventional study was conducted on patients who had a history of phacoemulsification and monofocal IOL implantation without any complications at least six months before the intervention. One drop of 1% pilocarpine solution was instilled in one of the patients' eyes, and near and distance visual acuity was assessed before and 20 minutes after monocular administration of the drop. Adverse effects were monitored for 8 hours.</p><p><strong>Results: </strong>We studied54 pseudophakic eyes of 54 patients with a mean age of 55.02 <math><mo>±</mo></math> 10.10 years, including 36 males (66.7%). Distance-corrected near visual acuity improved significantly after administering 1% pilocarpine (<i>P</i> <math><mo><</mo></math> 0.001). After treatment, no significant decrease in corrected distance visual acuity (CDVA) was observed (<i>P</i> = 0.60). Overall, 46 patients (85.2%) exhibited an improvement of more than one line in near vision after treatment; however, eight patients (14.8%) did not show any changes in near vision. Only two patients (3.7%) gained three lines in near vision. Headache, irritation, and nausea were observed in three patients, two patients, and one patient, respectively.</p><p><strong>Conclusion: </strong>The monocular 1% pilocarpine solution significantly improved near visual acuity among patients with pseudophakia and featured an acceptable safety profile. Although this improvement is considerable, it may not be sufficient for complete spectacle independence. <b>Trial registration:</b> ClinicalTrials.gov identifier: NCT05578001.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing ChatGPT-3.5 to Assist Ophthalmologists in Clinical Decision-making.","authors":"Samir Cayenne, Natalia Penaloza, Anne C Chan, M I Tahashilder, Rodney C Guiseppi, Touka Banaee","doi":"10.18502/jovr.v20.14692","DOIUrl":"10.18502/jovr.v20.14692","url":null,"abstract":"<p><strong>Purpose: </strong>ChatGPT-3.5 has the potential to assist ophthalmologists by generating a differential diagnosis based on patient presentation.</p><p><strong>Methods: </strong>One hundred ocular pathologies were tested. Each pathology had two signs and two symptoms prompted into ChatGPT-3.5 through a clinical vignette template to generate a list of four preferentially ordered differential diagnoses, denoted as Method A. Thirty of the original 100 pathologies were further subcategorized into three groups of 10: cornea, retina, and neuro-ophthalmology. To assess whether additional clinical information affected the accuracy of results, these subcategories were again prompted into ChatGPT-3.5 with the same previous two signs and symptoms, along with additional risk factors of age, sex, and past medical history, denoted as Method B. A one-tailed Wilcoxon signed-rank test was performed to compare the accuracy between Methods A and B across each subcategory (significance indicated by <i>P</i> <math><mo><</mo></math> 0.05).</p><p><strong>Results: </strong>ChatGPT-3.5 correctly diagnosed 51 out of 100 cases (51.00%) as its first differential diagnosis and 18 out of 100 cases (18.00%) as a differential other than its first diagnosis. However, 31 out of 100 cases (31.00%) were not included in the differential diagnosis list. Only the subcategory of neuro-ophthalmology showed a significant increase in accuracy (<i>P</i> = 0.01) when prompted with the additional risk factors (Method B) compared to only two signs and two symptoms (Method A).</p><p><strong>Conclusion: </strong>These results demonstrate that ChatGPT-3.5 may help assist clinicians in suggesting possible diagnoses based on varying complex clinical information. However, its accuracy is limited, and it cannot be utilized as a replacement for clinical decision-making.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bulbar Conjunctival Thickness in Eyes with Pseudoexfoliation Measured by Anterior Segment OCT.","authors":"Mahla Shadravan, Shahin Yazdani, Bahareh Kheiri, Farideh Sharifipour, Azadeh Doozandeh, Mohammad Mehdi Hatami, Neda Einollahi","doi":"10.18502/jovr.v20.15341","DOIUrl":"10.18502/jovr.v20.15341","url":null,"abstract":"<p><strong>Purpose: </strong>Eyes with pseudoexfoliation demonstrate fragile intraocular structures. The current study evaluated conjunctival thickness in pseudoexfoliation eyes as compared to a control group.</p><p><strong>Methods: </strong>In this cross-sectional study, patients with pseudoexfoliation and an age-matched control group underwent measurement of bulbar conjunctival thickness in the superior and temporal quadrants, 1, 2, and 3 mm posterior to the limbus using anterior segment OCT.</p><p><strong>Results: </strong>A total of 140 eyes of 140 subjects including 68 eyes of 68 patients with pseudoexfoliation and 72 eyes of 72 control subjects without pseudoexfoliation were studied. Both study groups were divided into two subgroups - those using glaucoma drops versus medication-free eyes. Total conjunctival thickness in pseudoexfoliation eyes was significantly lower than control eyes across all comparisons. Conjunctival thickness in the superior quadrant 1, 2, and 3 mm from the limbus was 177.62 <math><mo>±</mo></math> 41.30, 235 <math><mo>±</mo></math> 48.41, and 231.40 <math><mo>±</mo></math> 49.81 µm, respectively in the pseudoexfoliation group versus 207.49 <math><mo>±</mo></math> 48.92, 265.67 <math><mo>±</mo></math> 52.66, and 262.74 <math><mo>±</mo></math> 59.43 µm in the control group (<i>P</i> <math><mo><</mo></math> 0.001, <math><mo><</mo></math> 0.001, and 0.001, respectively). In the temporal quadrant, conjunctival thickness 1, 2, and 3 mm from the limbus was 193.62 <math><mo>±</mo></math> 46.97, 198.19 <math><mo>±</mo></math> 54.67, and 178.59 <math><mo>±</mo></math> 57.90 µm, respectively in the pseudoexfoliation group versus 213.76 <math><mo>±</mo></math> 47.06, 224.50 <math><mo>±</mo></math> 56.24, and 210.26 <math><mo>±</mo></math> 63.70 µm in the control group (<i>P</i> = 0.012, 0.006, and 0.003, respectively).</p><p><strong>Conclusion: </strong>Conjunctival thickness was significantly less in pseudoexfoliation eyes than an age-matched control group which supports clinical observations of thinner and more fragile conjunctiva in these eyes with implications for glaucoma surgery.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case-Control Study of Toric Intraocular Lens Implantation in Congenital Cataract.","authors":"Lukpan Orazbekov, Neilya Aldasheva, Aidana Sutbayeva, Kairat Ruslanuly","doi":"10.18502/jovr.v20.14282","DOIUrl":"10.18502/jovr.v20.14282","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the visual and refractive outcomes after toric intraocular lens (IOL) implantation compared to monofocal IOLs in pediatric eyes with cataracts and preexisting corneal astigmatism.</p><p><strong>Methods: </strong>This case-control study was performed on 37 eyes of 37 children older than six years with visually significant congenital cataracts and corneal astigmatism greater than 1.75 diopters (D). The patients underwent lens aspiration with either monofocal (19 eyes) or toric (18 eyes) IOL implantation between June 2021 and December 2022. Uncorrected distance visual acuity (UCVA), corrected distance visual acuity (CDVA), near visual acuity, keratometry data, and residual astigmatism were evaluated preoperatively and on the fifth day as well as the first, third, and sixth months postoperatively.</p><p><strong>Results: </strong>Preoperative mean corneal astigmatism was 2.84 <math><mo>±</mo></math> 0.51 D in the toric group and 3.05 <math><mo>±</mo></math> 0.79 D in the non-toric group (<i>P</i> = 0.563). At the final follow-up, postoperative refractive astigmatism was 0.53 <math><mo>±</mo></math> 0.33 D in the toric group and 2.33 <math><mo>±</mo></math> 0.8 D in the non-toric group (<i>P</i> <math><mo><</mo></math> 0.001). CDVA of 20/40 or better was achieved in 83.3% (<i>n</i> = 15) and 47.4% (<i>n</i> = 9) of eyes in the toric and non-toric groups, respectively (<i>P</i> = 0.038). Also, corrected near visual acuity of 20/40 or better was achieved in 100% (<i>n</i> = 18) and 78.9% (<i>n</i> = 15) of eyes in the toric and non-toric groups, respectively (<i>P</i> = 0.105).</p><p><strong>Conclusion: </strong>The study shows that pediatric cataract surgery with toric IOL implantation is an effective method of correcting preexisting corneal astigmatism. Compared to monofocal IOL implantation, it achieves better CDVA and near visual acuity.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Biometric Comparison Between Myopic and Non-myopic Eyes Treated for Retinopathy of Prematurity.","authors":"Kaveh Abri Aghdam, Samira Chaibakhsh, Nazanin Hasani, Vahid Zare Hosseinabadi, Ali Aghajani","doi":"10.18502/jovr.v20.14953","DOIUrl":"10.18502/jovr.v20.14953","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to assess the biometric alterations contributing to myopia in children who have undergone treatment for retinopathy of prematurity (ROP) and compare these changes with those observed in full-term myopic children.</p><p><strong>Methods: </strong>Children who had undergone ROP treatment were recruited and classified according to their treatment methods. An age-matched group of myopic patients with no history of ROP treatment was also included. Complete perinatal history was collected, and a comprehensive ophthalmic examination, including cycloplegic refraction, was conducted. The biometric data of children in each study group were gathered using the IOL Master and Pentacam.</p><p><strong>Results: </strong>The study recruited 14 patients in the intravitreal bevacizumab (IVB) group, 17 patients in the laser-treated group, and 13 individuals in the control group. There was no significant difference between the two patient groups regarding gestational age, birth weight, and age. In the IVB group, 50% of patients were myopic, compared to 52.9% in the laser-treated group. The incidence of high myopia was significantly higher in the laser-treated group (<i>P</i> <math><mo><</mo></math> 0.001). In the non-myopic group, changes in refractive error were solely related to changes in axial length (<i>P</i> = 0.003). However, in the myopic group, changes in refractive error were significantly associated with changes in anterior chamber depth (<i>P</i> <math><mo><</mo></math> 0.001), lens thickness (<i>P</i> <math><mo><</mo></math> 0.001), and axial length (<i>P</i> = 0.018). Furthermore, myopic children in the ROP group had significantly shorter axial lengths, shallower anterior chambers, thicker lenses, and steeper corneas compared to the control group (all <i>P</i> <math><mo><</mo></math> 0.001).</p><p><strong>Conclusion: </strong>Eyes with a history of ROP treatment, whether myopic or non-myopic, should be considered distinct entities. In patients who have undergone ROP treatment and have not developed myopia, changes in refractive error are primarily influenced by alterations in axial length, rather than changes in the anterior segment. Furthermore, children with myopia and a history of treatment for ROP (either IVB or laser) exhibit different biometric changes compared to myopic children without a history of ROP treatment, further underscoring their unique characteristics.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Star of the Diabetic Macular Show: Stellate Nonhereditary Idiopathic Foveomacular Retinoschisis (SNIFR).","authors":"Cory A Christensen, Neha Gupta, Mark P Breazzano","doi":"10.18502/jovr.v20.15125","DOIUrl":"10.18502/jovr.v20.15125","url":null,"abstract":"","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis.","authors":"Diego Dominguez, Sawyer Vaclaw, Cynthia K McClard, Matlock A Jeffries, Jila Noori","doi":"10.18502/jovr.v20.14952","DOIUrl":"10.18502/jovr.v20.14952","url":null,"abstract":"<p><strong>Purpose: </strong>Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic uveitis. Janus kinase (JAK) inhibitors, one of the newest biologics, have shown successful outcomes in treating autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases by suppressing the JAK/signal transducers and transcription (STAT) pathway. We present two cases of recalcitrant chronic uveitis with significant improvement in intraocular inflammation by using upadacitinib, a selective JAK1 inhibitor.</p><p><strong>Case reports: </strong>The first case is a 59-year-old female with HLA-B27-positive Chron's disease and chronic anterior and intermediate uveitis who experienced an improvement in visual acuity, anterior chamber and vitreous inflammation, and cystoid macular edema on upadacitinib. The second patient is a 71-year-old female with birdshot chorioretinopathy, intolerant of initially used systemic immunosuppressive agents who showed significant improvement in vitreous inflammation, retinal phlebitis, and choroiditis after treatment with upadacitinib.</p><p><strong>Conclusion: </strong>Utilizing JAK inhibitors such as upadacitinib in treating uveitis, whether in isolated forms or in the context of systemic autoimmune diseases, may require further evaluation by controlled cohort studies.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Complementary Touch for the Temporal Inverted Internal Limiting Membrane Flap Technique.","authors":"Levent Karabas, Ecem Önder Tokuç, Sevim Ayça Seyyar, Özlem Şahin","doi":"10.18502/jovr.v20.14516","DOIUrl":"10.18502/jovr.v20.14516","url":null,"abstract":"<p><p>The temporal inverted internal limiting membrane (ILM) flap technique was developed to improve vitreoretinal surgery for large macular holes (MH). However, in addition to the difficulty of the surgical procedure, the main concern is the displacement of the ILM flap due to small fluid leakage into the posterior pole, even in the short time required to close the sclerotomies after fluid-air exchange. A new approach to the temporal inverted ILM flap technique is described here. In this approach, when the ILM flap is inverted over the MH, ILM forceps, while it is closed, are gently pressed over the folded edge and passed over (just like folding a paper in half), creating an ILM fold mark like the ones used in origami. Thus, it can be seen that the minimal fluid leaking into the posterior pole ventilates the free edge of the flap, but the force formed along the folded edge prevents the flap turnover.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"20 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}